AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics
(Thomson Reuters ONE) -
MorphoSys AG /
AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the
Development of Novel Antibody Therapeutics
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
New Product Category Targets Contract Research Organizations and Pharmaceutical
Companies
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its
division for research and diagnostic antibodies, AbD Serotec, will launch a
series of novel anti-drug antibodies (ADAs) to strengthen its position as a
leading provider of diagnostic reagents. Starting with the recent launch of
fully human, recombinant antibodies binding Rituximab (Rituxan(®)) and
Trastuzumab (Herceptin(®)), AbD Serotec plans to expand this product category
with antibodies against Alemtuzumab (Campath(®)), Bevacizumab (Avastin(®)),
Infliximab (Remicade(®)), Ustekinumab (Stelara(®)), and Adalimumab (Humira(®))
in the near future.* Other anti-drug antibodies can be requested as part of the
custom antibody service of AbD Serotec.
"Anti-drug antibodies are ideal for preclinical and clinical research to support
the development of novel antibody drugs as well as biosimilars," commented
Dieter Feger, Head of AbD Serotec. "We see an increasing demand for these tools
from clinical research organizations, biopharmaceutical and pharmaceutical
companies. Due to the recombinant nature of our HuCAL technology, AbD Serotec is
able to deliver an unlimited, secure and batch to batch consistent supply of
these assay reagents for extensive clinical studies."
The Human Combinatorial Antibody Library can deliver highly specific, high-
affinity monoclonal antibodies against any given antibody drug with
unprecedented success rates. The highly specific HuCAL ADAs are developed solely
in vitro, pre-adsorbed against any available controls and human serum. An option
to screen for inhibiting or neutralizing antibodies is also offered. An
unlimited, consistent supply eliminates the need for revalidation of new sources
in extensive clinical studies. Other advantages include the possibility to
convert selected ADAs into various other human isotypes and Ig subclasses. This
provides customers with a single antibody solution for both immune response and
pharmacokinetic assays ultimately saving assay development resources.
* Not all anti-drug antibodies might be available in all countries
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1613966/514086.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1613966]
Unternehmensinformation / Kurzprofil:
Datum: 23.05.2012 - 07:31 Uhr
Sprache: Deutsch
News-ID 149123
Anzahl Zeichen: 5719
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
